« Back
Quantitative Cell-Based Bioassays for Individual or Combination Immune Checkpoint Immunotherapy
Poster Title: Quantitative Cell-Based Bioassays for Individual or Combination Immune Checkpoint Immunotherapy
Submitted on 25 May 2017
Author(s): Jamison Grailer, Pete Stecha, Julia Gilden, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Affiliations: Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
Poster Views: 1,858
View poster »

Poster Information
Abstract: Immunotherapy aims to boost a patient’s own immune system to fight disease. Activation of T cells via direct stimulation of the T cell receptor or by modulating immune checkpoint pathways are two strategies being employed individually and in combination. Immune checkpoint targets include co-inhibitory (e.g. PD-1, CTLA-4, TIGIT, LAG-3) and co-stimulatory (e.g. GITR, 4-1BB, OX40, CD40) receptors. Summary: Cell-based reporter bioassays overcome the limitations of primary cell-based assays for functional characterization of antibody and other biologics drugs targeting individual or combination immune checkpoint receptors. Here we show a portfolio of immune inhibitory checkpoint bioassays targeting PD-1/PD-L1, TIGIT/CD155, CTLA4/CD80/86 and LAG3/MHCII, that can be used for antibody screening, characterization, potency and stability studies.Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Creative BioMart

Cytotoxicity of Environmental Toxins PFOA and Gen X
Lauren Zane, Thomas Schultz

Superoxide Dismutase
Creative Enzymes

a comparison of dispense performance of manual pipetting versus automated pipetting for assay development
Anne F. Hammerstein, David J. Onley, Joby Jenkins, Paul G. Wylie, Sarah Payne

ExpiSf™ Expression system: A Chemically Defined Baculovirus-Based System for Enhanced Protein and Virus Production in Sf9 Cells
Kenneth Thompson, Maya Yovcheva, Sara Barnes, Melissa Cross, Katy Irvin, Natasha Lucki, Henry Chiou, and Jonathan Zmuda